医薬品の開発に
「実りある」
患者・市民参画を育てる
Multi-stakeholder Co-creation
Social co-creation with patients and public
Inclusive and sustainable participation from diverse backgrounds
Equitable and reciprocal benefits
Ongoing opportunities for mutual learning – not just receiving support or making requests
Concrete actions
Robust planning to return value to society
Clinical Trial Ambassador Project
Empirical research 'Using PED as Evidence'
A pilot case study 'Building PED using metaverse'
Patient-focused clinical trial ecosystem
Supporting citizen science
Interdisciplinary Approach to Science
Empirical research activities that foster patient and public involvement (PPI)
A Focus on Societal Implementation
Consultation to implement PPI
We offer consultations on PPI
in medicines development and clinical research.
Our team—representing various professional backgrounds—works with
companies, researchers, healthcare providers, and patient groups
to help put PPI into practice.
Participation in PFMD's initiative
Patient engagement and patient experience data
Patient engagement in health technology assessment
Global clinical trials ecosystem
Co-hosted by 1st PEOF+ Asia Pacific in Manila in 2026.
A Global Perspective
Systematizing PPI through international collaboration
Events & Projects
Our Milestones
2020 In Austria, Boehringer Ingelheim and European Patients' Academy on Therapeutic Innovation (EUPATI) jointly launched the Clinical Trial Ambassador Project. The first training sessioin for patient organisations was delivered.
2021 Bringing Patient Education to Japan - Boehringer Ingelheim, patient organisations, and researchers comes together to design a Japanese version of the Clinical Trial Ambassador Project.
2022 Collaboration beyond Organizational Boundaries - Volunteers from pharmaceutical companies, patient organisations, and academia worked togather to deliver the first Clinical Trial Ambassador Training program in Japan. Six patient representatives completed the training and became Clinical Trial Ambassadors.
2024 Expanding Innovation for Society - To strengthen the public value, transparency, and credibility of the Project, its governing body was established as nonprofit. On April 25, YORIAILab was officially founded.
2025 Building a Co-creation Community - To further advance PPI in healthcare and medicines development, YORIAILab expanded its activities beyond the Clinical Trial Ambassador Project, strengthening education, partnerships, and research. By August 2026, more than 60 patients and members of the public had completed the training program and becoming contributors to a growing co-creation community.
Highlights
Latest information on events and resources ➡️
Clinical Trial Ecosystem
To advance a healthcare ecosystem shaped by patient perspectives, we contribute to discussions on the implementation of Decentralized Clinical Trials (DCTs). We organize standing workshops with Clinical Trial Ambassadors to explore the future of DCTs from the patient perspective. We also collaborate with medical institutions to support the implementation of PPI in clinical research.
News
Latest information on events and resources ➡️
2026.9.5 [Latest ]
We have changed the YORIAILab domain name from yoriailab.com to yoriailab.org. This change reflects our commitment as a non-profit organization dedicated to social co-creation and community collaboration. If you continue to access yoriailab.com, you will be automatically redirected to yoriailab.org, so no action is required on your part. Thank you for your continued support of YORIAILab.
.
2026.9.1 [Latest ]
We have revised our membership rules and introduced a new Student Membership category in addition to our existing membership types. Student Members can join YORIAILab’s Steering Committee and enjoy member benefits for an annual fee of ¥1,000. As a special benefit for interns, former internship participants may continue to receive the same benefits as Special Members for up to three years after graduation while paying the Student Membership fee. We look forward to welcoming many students to YORIAILab.
2026.8.26
We held orientation sessions for the 7th Clinical Trial Ambassador Training Program on the 24th and 26th. Twenty-two participants representing diverse backgrounds and perspectives will learn and grow together over the next six months.
2026.8.22
The Palmoplantar Pustulosis Patient Association PPP Community has joined YORIAILab as a partner organization. We hope to further expand our network of connections and collaborative efforts with this new member. We look forward to your continued support.
2026.8.20
Today, we held the kickoff meeting for the International Affairs Team, which was established at our regular general meeting in June. We started with six members. Building on our collaboration with PFMD over the past several years, we will clarify the objectives and results of YORIAILab's international activities going forward, and promote partnerships with internationally active patient support organizations, participation of team members in discussions on various international projects, and the dissemination of information and sharing of knowledge overseas.
2026.8.18
We held our 23rd Lunchtime Short Seminar. Ms. Manami Fujii from Fukuyama University gave a lecture on "Experiences as a Sibling of a Child with Disability." Her talk provided an opportunity to think about how to support siblings of children with disabilities, based on the feelings, struggles, and interactions with family and those around them.
2026.8.18
The report from the 3rd Joint Study Session of Skin Disease Patient Organizations , which we helped organize on June 27th, has been shared. An English translation (YORIAILab translation) is also included.
2026.8.11
Drug Development: We have expanded the content on our Learning Resources page➡️. We have added a significant amount of information on websites and publications where you can learn about drug development and clinical trials.
2026.8.9
At the Japan Cancer Forum, we exhibited an awareness booth on clinical trials and patient/citizen participation over two days, August 8th and 9th. More than 200 people visited our booth. On the first day at the event venue, we conducted a simulated experience of the recently popular Patient Preference Study, and more than 30 people participated in the live experience.
2026.8.8
We've created a flyer to help patients and the public learn more about Patient Experience Data (PED), which utilizes patients' experiences to improve healthcare. Please feel free to use it.
2026.7.29
All curriculum for the 6th Clinical Trial Ambassador Training Program has been completed. Those who have completed the training will now be active in various fields as Clinical Trial Ambassadors. We look forward to working with you.
2026.7.21
We held our 22nd Lunchtime Short Seminar. We explained the key points for interpreting the currently trending international regulatory guidelines on patient preference information, from the perspective of patient and public participation (PPI). This topic will also be covered at the DIA Bioethics Community Seminar (held online on August 25th, free of charge, co-sponsored by YORIAILab) ➡️ . If you would like to learn more in-depth, please join us there as well.
2026.7.15
At the 7th installment of "Make Hope, Create the Future" – Turning Patient Value into Data: PED, Patient Preferences, HTA, and the Ethics of its Use – (hosted by the NPO Lung Cancer Patients Association One Step, via YouTube Live) ➡️ , I spoke with Hayley Chapman of PFMD about our efforts to turn patient value into data (Patient Experience Data).
Public consultation
Public comment collection on new systems and guidelines regarding patient and public involvement
There are currently no open public consultations.
If you have any questions, please contact us here: ✉ nobutaka.yagi@yoriailab.com
